---
figid: PMC4073101__nihms-462233-f0003
figtitle: Cilia and cilia-associated proteins in cancer
organisms:
- Homo sapiens
- Mus musculus
- Danio rerio
- Lareunionomyces loeiensis
- Corynebacterium phage gamma
pmcid: PMC4073101
filename: nihms-462233-f0003.jpg
figlink: /pmc/articles/PMC4073101/figure/F3/
number: F3
caption: Inactivation of VHL in RCC cells triggers a cascade of signaling and HIFα-dependent
  transcription that promote tumor growth cell autonomously, and by influencing angiogenesis
  in adjacent endothelial cells. Drugs currently approved in the therapy of RCC interfere
  with the downstream effectors of HIFα, including VEGF (bevacizumab), receptor tyrosine
  kinases (RTKs) like VEGFR and PDGFR (sunitinib, sorafenib, pazopanib, axitinib),
  and the m-TOR pathway (temsirolimus, everolimus). Ongoing preclinical studies suggest
  further potential targets with some of them overlapping with the potential targets
  in the treatment of ciliopathies such as polycystic kidney disease (green). These
  targets include mTOR, SRC, STAT and the RAS/RAF/MEK/ERK pathway. VEGF(R), vascular
  endothelial growth factor (receptor); PDGF(R), platelet derived growth factor (receptor);
  IGF(R), insulin-like growth factor (receptor); ANG-4, angiopoetin-4; TGFα, transforming
  growth factor alpha; JMJD1A/JMJD2B, jumonji domain-containing protein 1A/2B; JARID1B,
  lysine-specific demethylase 5B; LDH, lactate dehydrogenase A chain; c-MET, hepatocyte
  growth factor receptor; ROR2, RTK-like orphan receptor 2; MMP2, matrix metalloproteinase-2;
  IL6R, interleukin-6 receptor; STAT3, signal transducer and activator of transcription
  3; HGF, hepatocyte growth factor; EGFR, epidermal growth factor receptor; TIE2,
  Tyrosine-protein kinase receptor-2; PI3K, phosphatidylinositol 3-kinase; MEK, mitogen-activated
  protein kinase kinase 1; ERK, extracellular-regulated kinase; PLCγ phospholipase
  C-gamma; NO, nitric oxide; PKC, protein kinase C.
papertitle: Cilia and cilia-associated proteins in cancer.
reftext: Tamina Seeger-Nukpezah, et al. Drug Discov Today Dis Mech. ;10(3-4):e135-e142.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9751334
figid_alias: PMC4073101__F3
figtype: Figure
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
redirect_from: /figures/PMC4073101__F3
ndex: 94db0509-dec0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4073101__nihms-462233-f0003.html
  '@type': Dataset
  description: Inactivation of VHL in RCC cells triggers a cascade of signaling and
    HIFα-dependent transcription that promote tumor growth cell autonomously, and
    by influencing angiogenesis in adjacent endothelial cells. Drugs currently approved
    in the therapy of RCC interfere with the downstream effectors of HIFα, including
    VEGF (bevacizumab), receptor tyrosine kinases (RTKs) like VEGFR and PDGFR (sunitinib,
    sorafenib, pazopanib, axitinib), and the m-TOR pathway (temsirolimus, everolimus).
    Ongoing preclinical studies suggest further potential targets with some of them
    overlapping with the potential targets in the treatment of ciliopathies such as
    polycystic kidney disease (green). These targets include mTOR, SRC, STAT and the
    RAS/RAF/MEK/ERK pathway. VEGF(R), vascular endothelial growth factor (receptor);
    PDGF(R), platelet derived growth factor (receptor); IGF(R), insulin-like growth
    factor (receptor); ANG-4, angiopoetin-4; TGFα, transforming growth factor alpha;
    JMJD1A/JMJD2B, jumonji domain-containing protein 1A/2B; JARID1B, lysine-specific
    demethylase 5B; LDH, lactate dehydrogenase A chain; c-MET, hepatocyte growth factor
    receptor; ROR2, RTK-like orphan receptor 2; MMP2, matrix metalloproteinase-2;
    IL6R, interleukin-6 receptor; STAT3, signal transducer and activator of transcription
    3; HGF, hepatocyte growth factor; EGFR, epidermal growth factor receptor; TIE2,
    Tyrosine-protein kinase receptor-2; PI3K, phosphatidylinositol 3-kinase; MEK,
    mitogen-activated protein kinase kinase 1; ERK, extracellular-regulated kinase;
    PLCγ phospholipase C-gamma; NO, nitric oxide; PKC, protein kinase C.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Mtor
  - Tgfa
  - Angpt4
  - Vegfa
  - Aurka
  - Nedd9
  - Vhl
  - Ror2
  - Rora
  - Mmp2
  - Kdm5b
  - Kdm4b
  - Kdm3a
  - Stat3
  - Ldha
  - Ccnd1
  - Met
  - Egfr
  - Hgf
  - Pdgfrb
  - Tek
  - Hspg2
  - Src
  - Pik3r1
  - ras
  - Hras
  - Kras
  - Rem1
  - Akt1
  - Zhx2
  - Mdk
  - Ephb2
  - Mapk1
  - Prkd1
  - XRCC1
  - PBRM1
  - MTOR
  - HIF1A
  - EPAS1
  - HIF3A
  - TGFA
  - ANGPT4
  - IGF1
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - AURKA
  - NEDD9
  - VHL
  - ROR2
  - RORA
  - MMP2
  - KDM5B
  - KDM4B
  - KDM3A
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - WNT1
  - WNT2
  - WNT2B
  - WNT3
  - WNT3A
  - WNT4
  - WNT6
  - WNT7A
  - WNT7B
  - WNT8A
  - WNT8B
  - WNT9A
  - WNT9B
  - WNT10A
  - WNT10B
  - WNT11
  - WNT16
  - WNT5A
  - WNT5B
  - STAT3
  - LDHA
  - CCND1
  - MET
  - EGFR
  - IGF1R
  - HGF
  - IL6
  - SOS1
  - PDGFRB
  - PDGFRA
  - TEK
  - KDR
  - FLT1
  - FLT4
  - HSPG2
  - PLCE1
  - PLCZ1
  - PLCB1
  - PLCB2
  - PLCB3
  - PLCB4
  - PLCD1
  - PLCD3
  - PLCD4
  - PLCG1
  - PLCG2
  - SRC
  - FGR
  - FYN
  - YES1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - KRAS
  - HRAS
  - NRAS
  - AKT1
  - AKT2
  - AKT3
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - SOAT1
  - STAT1
  - STAT2
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - EPHB2
  - MAPK1
  - MAPK3
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - PRKD1
  - mtor
  - tgfa
  - igfn1.2
  - vegfaa
  - aurka
  - nedd9
  - vhl
  - ror2
  - mmp2
  - kdm5ba
  - kdm4b
  - stat3
  - ldha
  - ccnd1
  - met
  - egfra
  - tek
  - src
  - rab1ab
  - stat1b
  - stat4
  - temsirolimus
  - pazopanib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
